There are currently 931 clinical trials in Durham, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Duke University Medical Center, Duke University, Duke Comprehensive Cancer Center and Duke University health system. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
NCT04358393
Recruiting
This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Duke University, Durham, North Carolina
Conditions: AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
NCT05987189
Recruiting
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/12/2024
Locations: Duke University Health System, Durham, North Carolina
Conditions: Lung Cancer
Register for Updates
Computational Modeling of Cleft Lip Nasal Deformity and Assessment of Nasal Function and Treatment Outcomes
NCT04150783
Recruiting
The purpose of this study is to use computers to simulate airflow in 3D construction of your nasal cavity generated from cone beam CT images. The results from computer simulations will help researchers identify the severity of cleft-induced nasal dysfunction and assess the impact of current treatment in restoring breathing function. The ultimate goal is to improve post-surgery outcomes to restore nasal breathing function to normal levels.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Duke University Medical Center and affiliated practices, Durham, North Carolina
Conditions: Cleft Lip and Nose, Nasal Obstruction
Register for Updates
BlueWind RENOVA iStim™ System for the Treatment of OAB
NCT03596671
Recruiting
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Gender:
Female
Ages:
Between 18 years and 80 years
Trial Updated:
12/29/2023
Locations: Duke Urogynecology, Durham, North Carolina
Conditions: Treatment of Patients Suffering From Overactive Bladder (OAB)
Register for Updates
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485
Recruiting
FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.
Gender:
All
Ages:
Between 6 months and 25 years
Trial Updated:
12/21/2023
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Low-grade Glioma, Advanced Solid Tumor
Register for Updates
Recovery and Outcomes From Stroke
NCT04007757
Recruiting
The investigators will perform follow-up on 500 cases of deep and lobar intracerebral hemorrhage to perform advanced neuroimaging before 45 days post stroke, and evaluations of motor and cognitive function at baseline, 3 months and 6 months to determine predictors of recovery, progressive cognitive or functional impairment.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: Duke University, Durham, North Carolina
Conditions: Intracerebral Hemorrhage
Register for Updates
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
NCT01745237
Recruiting
The primary objective of this study was to determine the ability of cardiac magnetic resonance (CMR) to identify cardiac involvement in patients with sarcoidosis. Patients were to undergo CMR in addition to routine clinical evaluation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Sarcoidosis
Register for Updates
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
NCT03567889
Recruiting
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Duke University Medical Center - Duke Cancer Center, Durham, North Carolina
Conditions: Melanoma Stage IIIB/C
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Labor Status Monitor for Diagnosing True vs False Labor in Preterm Patients
NCT06157203
Recruiting
This is an observational study of pregnant persons in threatened labor. The study device will record electromyography signals, then the signals will be examined to determine who is in true labor and who is in threatened labor. The two goals are: To establish the thresholds for the Contraction Synchronization Index (CSI) and the False Labor Index (FSI) to be used by the Labor Status Monitor to diagnose in-Labor or Not-in-Labor for preterm patients with threatened labor To obtain feedback from su... Read More
Gender:
Female
Ages:
All
Trial Updated:
11/27/2023
Locations: Dume University Medical Center, Durham, North Carolina
Conditions: PreTerm Labor, Threatened Preterm Labor, Preterm Birth
Register for Updates